Study Assesses Duration of Scalp Cooling to Prevent Alopecia

A 20-minute post-infusion cooling time is effective and tolerable for patients treated with scalp cooling to prevent docetaxel-induced alopecia.
A 20-minute post-infusion cooling time is effective and tolerable for patients treated with scalp cooling to prevent docetaxel-induced alopecia.

A 20-minute post-infusion cooling time is effective and tolerable for patients treated with scalp cooling to prevent docetaxel-induced alopecia in patients with cancer, a study published online ahead of print in the journal Supportive Care in Cancer has shown.1

For patients undergoing chemotherapy for cancer, chemotherapy-induced alopecia can be one of the most distressing adverse reactions to treatment.

Scalp cooling can minimize or prevent chemotherapy-induced alopecia, but the optimal time of cooling is not clear. Because a previous study on post-infusion cooling time in patients treated with docetaxel demonstrated no difference between 90 and 45 minutes, researchers sought to determine if a postinfusion cooling time of less than 45 minutes could be effective.

For the multicenter, prospective study, investigators enrolled 134 patients who initiated treatment with docetaxel 75 to 100 mg/m2 intravenously in 3-weekly cycles. Participants were randomly assigned 1:1 to receive post-infusion scalp cooling for 45 minutes or 20 minutes.

Researchers found that scalp cooling results were similar between the 2 groups. A total of 73% of patients treated with 20 minutes of cooling did not require a form of head covering compared with 79% of those treated with 45 minutes of postinfusion cooling (P=.5).

The study also demonstrated that the procedure was well tolerated, with only 6 patients discontinuing scalp cooling due to intolerance during the first cycle of chemotherapy.

REFERENCE

1. Komen MMC, Breed MPM, Smorenburg CH, et al. Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia [published online ahead of print January 25, 2016]. Supp Care Cancer. doi:10.1007/s00520-016-3084-7.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs